STOCK TITAN
  1. Home
  2. Sec-filings
  3. PCVX
  4. [Form 4] Vaxcyte, Inc. Insider Trading Activity

Vaxcyte CEO uses 6,289 shares to pay taxes

Vaxcyte CEO Grant Pickering surrendered 6,289 shares to the company to satisfy tax withholding on vested RSUs, not as open‑market sales.

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Vaxcyte, Inc. (PCVX) director and chief executive officer Grant Pickering reported two Form 4 transactions involving Common Stock that were dispositions solely to cover tax withholding on vested restricted stock units. On August 31, 2026, 2,862 shares were surrendered at $60.74 per share, and on September 2, 2026, 3,427 shares were surrendered at $61.58 per share, both to the issuer for tax obligations. No Rule 10b5-1 trading plan is reported, and additional shares are held indirectly through trusts for the benefit of his son and daughter.

Positive

  • None.

Negative

  • None.

Insights

Analyzing...

Insider PICKERING GRANT
Role CHIEF EXECUTIVE OFFICER
Type Security Shares Price Value
Tax Withholding Common Stock F1 3,427 $61.58 $211K
Tax Withholding Common Stock F1 2,862 $60.74 $174K
holding Common Stock F2 -- -- --
holding Common Stock F3 -- -- --
Holdings After Transaction: Common Stock — 446,958 shares (Direct); Common Stock — 266,430 shares (Indirect, By Children's Trust)
Footnotes (3)
  1. F1. Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs.
  2. F2. Shares are held directly by a trust for the benefit of the Reporting Person's son.
  3. F3. Shares are held directly by a trust for the benefit of the Reporting Person's daughter.
Shares surrendered on September 2, 2026 3,427 shares Common Stock delivered to issuer to cover tax withholding on RSU vesting at $61.58 per share
Price on September 2, 2026 tax withholding $61.58 per share Used to value 3,427 shares surrendered for tax withholding
Shares surrendered on August 31, 2026 2,862 shares Common Stock delivered to issuer to cover tax withholding on RSU vesting at $60.74 per share
Price on August 31, 2026 tax withholding $60.74 per share Used to value 2,862 shares surrendered for tax withholding
Total shares used for tax withholding 6,289 shares Combined shares surrendered across the two tax-withholding dispositions reported
Restricted Stock Units financial
"tax withholding obligations realized upon the vesting of RSUs"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
tax withholding obligations financial
"shares surrendered to the Issuer to cover applicable tax withholding obligations"
indirect ownership financial
"Shares are held directly by a trust for the benefit of the Reporting Person's son"

FAQ

What did Vaxcyte (PCVX) CEO Grant Pickering report in this Form 4?
He reported two dispositions totaling 6,289 shares of Vaxcyte Common Stock, surrendered to the issuer on August 31, 2026 and September 2, 2026 to cover tax withholding obligations from the vesting of restricted stock units (RSUs).

Were the PCVX share transactions by the CEO open-market sales?
No. The Form 4 states the transactions were payments of tax liability by delivering or withholding securities, with footnotes explaining the shares were surrendered to Vaxcyte to cover tax withholding upon RSU vesting, not sold in the open market.

How many Vaxcyte (PCVX) shares were used to cover taxes and at what prices?
The CEO surrendered 2,862 shares at $60.74 per share on August 31, 2026 and 3,427 shares at $61.58 per share on September 2, 2026, for a total of 6,289 shares delivered to satisfy tax withholding obligations.

Is there a Rule 10b5-1 trading plan associated with these PCVX transactions?
No. The filing’s Rule 10b5-1 checkbox is unchecked, and there is no footnote indicating that these tax-withholding dispositions were made under a pre‑arranged Rule 10b5‑1 trading plan.

Does the Vaxcyte CEO hold any PCVX shares indirectly?
Yes. The Form 4 shows indirect ownership through trusts, with footnotes stating that certain shares are held by a trust for the benefit of his son and a separate trust for the benefit of his daughter.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
PICKERING GRANT
(Last)(First)(Middle)
C/O VAXCYTE, INC.
825 INDUSTRIAL ROAD, STE. 300
(Street)
SAN CARLOS CALIFORNIA 94070
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Vaxcyte, Inc. [ PCVX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
CHIEF EXECUTIVE OFFICER
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/31/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/31/2026F2,862(1)D$60.74450,385D
Common Stock09/02/2026F3,427(1)D$61.58446,958D
Common Stock133,215IBy Children's Trust(2)
Common Stock133,215IBy Children's Trust(3)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs.
2. Shares are held directly by a trust for the benefit of the Reporting Person's son.
3. Shares are held directly by a trust for the benefit of the Reporting Person's daughter.
Remarks:
Grant Pickering, by /s/ Peter N. Efremenko, Attorney-In-Fact09/02/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR